Feed aggregator

Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts

World Pharma News - Wed, 06/23/2021 - 12:00
Novartis and Hewlett Packard Enterprise (HPE)announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines.

Drug doubles down on bone cancer, metastasis

World Pharma News - Wed, 06/23/2021 - 10:00
Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.

Chemist Han Xiao at Rice and biologist Xiang Zhang at Baylor and their labs have developed an antibody conjugate called BonTarg that delivers drugs to bone tumors and inhibits metastasis.

Under Fire From Investors, Walmsley Outlines Vision for GSK

Biospace news - Wed, 06/23/2021 - 02:00
CEO Emma Walmsley’s vision includes a projected $46 billion in annual sales from the stand-alone pharma company by 2031 and more than 10% operating profit over the next five years.

Likely Link between mRNA Vaccines and Rare Cases of Heart Inflammation, CDC Panel Says

Biospace news - Wed, 06/23/2021 - 02:00
Concerns over vaccination links to heart inflammation are valid, a U.S. Centers for Disease Control and Prevention advisory committee announced this afternoon.

FDA Releases Details About Internal Debate Over Biogen’s Aduhelm for Alzheimer’s

Biospace news - Wed, 06/23/2021 - 02:00
The drug was approved on June 7 under the agency’s accelerated approval pathway, despite the agency’s Peripheral and Central Nervous System Drugs Advisory Committee voting against the drug in November 2020 and having been assured at that time the agency was not considering an accelerated approval.

FDA approves first oral blood thinning medication for children

World Pharma News - Tue, 06/22/2021 - 12:00
The U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days.

BioNTech announces first patient dosed in Phase 2 clinical trial of mRNA-based BNT111 in patients with advanced melanoma

World Pharma News - Tue, 06/22/2021 - 10:00
BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). The study is evaluating the Company's therapeutic cancer vaccine candidate BNT111 in combination with Libtayo® (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.

Cuba’s COVID-19 Vaccine is 92% Effective, Late-Stage Trials Show

Biospace news - Tue, 06/22/2021 - 02:00
Cuba’s Abdala vaccine is 92% effective against the novel coronavirus, according to a recent analysis of late-stage trials.

COVID-19 Might Have Long-Term Effects on Sense of Taste and Smell, According to UK Researchers

Biospace news - Tue, 06/22/2021 - 02:00
Recent research shows those who had been hospitalized due to COVID-19 might already have a reduced sense of smell and taste, not just for the short term, but possibly for life.

COVID-19 News: New COVID-19 Vaccine Efficacy, MIS-C and More

Biospace news - Tue, 06/22/2021 - 02:00
Please check out the biopharma industry's COVID-19 stories that are trending for June 22, 2021.

Spruce's Drug Candidate Reduces Elevated Hormones in Classic CAH Patients

Biospace news - Tue, 06/22/2021 - 02:00
Spruce Biosciences shared results from two Phase II studies assessing tildacerfont, a non-steroidal, oral antagonist for the treatment of adult patients with classic CAH.

Hong Kong Biotech Scores $255 Million to Take First AI-Discovered Candidate to Clinic

Biospace news - Tue, 06/22/2021 - 02:00
Founded in 2014, Insilico focuses on using artificial intelligence for drug discovery and development.

Cantex Intends to Repurpose Failed Alzheimer’s Drug for Cancer Indications

Biospace news - Tue, 06/22/2021 - 02:00
Cantex forges a licensing deal with vTv Therapeutics and intends to evaluate the vTv drug as a potential treatment for several cancer-related issues.

SAB Biotherapeutics Combines With Blank Check Company to List on Nasdaq

Biospace news - Tue, 06/22/2021 - 02:00
The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.

Roche Presents Positive Clinical Data for Neurology Programs at EAN Annual Meeting

Biospace news - Tue, 06/22/2021 - 02:00
Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.

TRexBio Chomps Down on $59 Million Series A for Immunobiology

Biospace news - Tue, 06/22/2021 - 02:00
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.

ViiV Signs Licensing Deal for Halozyme's Tech to Create Long-Acting HIV Drugs

Biospace news - Tue, 06/22/2021 - 02:00
​Halozyme revealed that ViiV will pay $40 million upfront for the exclusive license to four small and large molecule targets and then pay the remaining $175 million in milestones.

GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab

World Pharma News - Mon, 06/21/2021 - 12:00
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced final, confirmatory results from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalisation or death among high-risk adult outpatients with mild-to-moderate COVID-19.

COVID-19 dual-antibody therapies effective against variants in animal study

World Pharma News - Mon, 06/21/2021 - 10:00
COVID-19 therapies made from antibodies often are given to patients who are at high risk of severe illness and hospitalization. However, there have been nagging questions about whether such antibody therapies retain their effectiveness as worrisome new virus variants arise.

Allogene Overland Biopharm Taps Cell Therapy Veteran Yao as CEO

Biospace news - Mon, 06/21/2021 - 02:00
Yao has more than 15 years of experience in the cell and gene therapy fields. He also established and directed the Cell Therapy R&D business unit, with a focus on CAR-T development.